Supporting Newborn Health Through Umbilical Cord Drug Testing
Protecting Newborns from the Very Start: How Umbilical Cord Testing Helps Families
When a baby is born, every decision in the delivery room feels important. For some families, questions about substance use during pregnancy add another layer of worry and uncertainty. Umbilical cord drug testing can help hospitals better understand a newborn’s needs and plan care that promotes the safety and well-being of both the newborn and the family.
At HNL Lab Medicine, umbilical cord testing is designed to support hospitals, clinicians, and families with timely, reliable information, not judgment. The goal is simple: help protect babies who cannot speak for themselves and connect families with the care and support they need as early as possible.
What is umbilical cord drug testing?
Umbilical cord drug testing provides hospitals and care teams with important information shortly after birth to help support newborn safety and guide family-centered care. By identifying possible prenatal substance exposure early, clinicians can better monitor infants, coordinate follow-up care, and connect families with supportive healthcare resources when needed.
Umbilical cord drug testing looks for evidence of certain substances that may have been used during the last trimester of pregnancy. After the baby is delivered, a small segment of the umbilical cord, tissue that would otherwise be discarded, is collected and sent to the laboratory for testing.
This approach offers several advantages for hospitals and families.
- The cord is available immediately after birth, so there is no need to wait for meconium (a baby’s first stool) to be passed.
- Collection is simple and fits naturally into standard delivery workflows.
- The cord can provide a broader picture of exposure over the later part of pregnancy, compared with urine tests that only reflect very recent use.
Because the specimen is collected right away, care teams are less likely to miss the opportunity to test when it is clinically appropriate.
Why early answers matter for newborns
For newborns, time matters. If a baby has been exposed to certain substances before birth, they may be at risk for symptoms such as withdrawal, feeding challenges, irritability, or breathing difficulties. When exposure is identified early, clinicians can:
- Monitor the baby more closely in the hospital
- Plan for appropriate treatment, if needed
- Make more informed decisions about when it is safe for the baby to go home
- Coordinate with pediatricians and other providers for follow-up care
Umbilical cord testing supports a more complete assessment, especially when a baby has symptoms that are difficult to explain or when information about substance use during pregnancy is limited.
Supporting parents with clarity and compassion
Parents often arrive at the hospital with a mix of emotions. Excitement, fear, hope, and sometimes worry. In situations where substance use is a concern, they may also feel ashamed or afraid of being judged. That is why it is so important for testing to be approached with compassion and clear communication.
Timely, objective results can help:
- Reduce uncertainty for parents during a stressful time
- Ground difficult conversations in facts rather than assumptions
- Open the door to honest discussion about next steps
- Connect families with counseling, treatment, or social support services when needed
HNL Lab Medicine uses definitive mass spectrometry testing (LC‑MS/MS), which offers high analytical sensitivity and specificity. This provides clinicians with strong, reliable data to support decision making, particularly in high-stake situations where reports to child welfare agencies or legal proceedings may be involved.
Focusing on safety through family-centered planning
In many states, hospitals develop a Plan of Safe Care for infants who have been prenatally exposed to substances. These plans are designed to protect the baby while also supporting the health and recovery of the parent or caregiver. They may include:
- Follow-up pediatric and maternal healthcare
- Substance use disorder treatment and recovery supports
- Mental health services
- Home visiting, early childhood services, or parenting support
- Coordination with child welfare agencies, when appropriate
Umbilical cord drug testing can help inform these plans by giving care teams a clearer picture of what the baby has been exposed to and what level of follow-up may be needed. The focus is on safety, stability, and support, not automatic separation of families.
Why hospitals choose in-house umbilical cord testing with HNL Lab Medicine
When hospitals rely on outside reference laboratories, newborn toxicology results can take a week or longer to return, leaving care teams and families waiting for answers during a critical window.
By performing qualitative umbilical cord drug testing in-house, HNL Lab Medicine helps close that gap so clinicians can act while the newborn is still in the hospital. Turnaround time is approximately 1 to 4 days from specimen receipt in the Toxicology Department (excluding weekends and holidays), supporting timely, informed decisions about monitoring, treatment, and discharge planning.
In-house testing also means specimens stay closer to home. Local processing reduces the risk of shipping delays or lost samples and keeps communication lines shorter between the laboratory and the care team. Clinicians have direct access to HNL Lab Medicine toxicology specialists for consultation and interpretation, allowing them to discuss complex cases, clarify results, and align testing strategies with hospital protocols.
Key benefits for hospitals and health systems include:
- Turnaround time of approximately 1 to 4 days from specimen receipt
- Definitive LC‑MS/MS methodology for high confidence in results
- Local processing that reduces shipping delays and lost samples
- Access to HNL Lab Medicine toxicology specialists for consultation and interpretation
By partnering with a regional laboratory that performs testing on-site, hospitals gain both speed and support. This combination helps ensure that drug exposure is identified promptly and that newborn care plans can be adjusted in real time to promote safety and stability for the baby and family.
A safer beginning for the smallest patients
Umbilical cord drug testing is ultimately about protection. It helps uncover information that might otherwise be missed, which allows clinicians to respond quickly, support parents more effectively, and put safeguards in place for the entire family.
By partnering with HNL Lab Medicine, hospitals can strengthen their newborn care programs with testing that is accurate, timely, and grounded in a shared commitment to the safety and well-being of every baby.
References and sites
ARUP Consult, Newborn Drug Screening - Meconium and Umbilical Cord Tissue: https://arupconsult.com/content/newborn-drug-testingPubMed, Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: https://pubmed.ncbi.nlm.nih.gov/27890824/
Casey Family Programs, Plans of Safe Care: https://www.casey.org/infant-plans-of-safe-care/
PMC, Drug Testing for Newborn Exposure to Illicit Substances in Pregnancy: https://pmc.ncbi.nlm.nih.gov/articles/PMC3139193/